What is the diagnosis and recommended management for a patient with thrombocytosis (platelet count ≈443 ×10⁹/L), high reticulocyte count, low serum iron, high unsaturated iron‑binding capacity, normal total iron‑binding capacity, and micro‑hypochromic anemia on peripheral smear?

Diagnosis: Iron Deficiency Anemia with Reactive Thrombocytosis

This patient has iron deficiency anemia (IDA) with secondary (reactive) thrombocytosis, confirmed by the constellation of low serum iron (4.8 μmol/L), high UIBC (56.2 μmol/L), microcytic-hypochromic red cells, and elevated platelet count (443 × 10⁹/L). The elevated reticulocyte count indicates an appropriate bone marrow response to anemia.

Diagnostic Interpretation

The laboratory pattern is pathognomonic for IDA:

• Low serum iron with high UIBC indicates depleted iron stores and increased transferrin availability
• Normal TIBC with high UIBC confirms the iron-deficient state
• Microcytic-hypochromic peripheral smear reflects inadequate hemoglobin synthesis
• Thrombocytosis (443 × 10⁹/L) is a well-documented reactive phenomenon in IDA 1

The normal ferritin requires context: while ferritin <15 μg/L is highly specific for iron deficiency (specificity 0.99), ferritin up to 45 μg/L may still indicate iron deficiency, particularly if inflammation is present, as ferritin is an acute phase reactant 2. A ferritin cut-off of 45 μg/L provides optimal sensitivity-specificity balance for diagnosing IDA 3, 2.

Mechanism of Thrombocytosis

The platelet elevation is directly related to iron deficiency severity. Research demonstrates that serum iron and transferrin saturation negatively correlate with platelet count—the more severe the iron deficiency, the higher the platelet count 4. This occurs through:

• Shared progenitor cell proliferation between megakaryocytic and erythroid lineages 5
• Compensatory hematopoietic responses under iron-deficient conditions 5

In one study, 8.1% of IDA patients developed thrombocytosis (platelets >450 × 10⁹/L), and these patients showed more severe anemia and advanced iron deficiency than those without thrombocytosis 1.

Management Algorithm

Step 1: Identify and Treat the Underlying Cause

Before initiating iron replacement, investigate the source of iron loss 3, 2:

• Gastrointestinal evaluation: Consider upper and lower endoscopy, particularly in men and postmenopausal women, as GI blood loss is the most common cause
• Menstrual history: In premenopausal women, assess for menorrhagia
• Dietary assessment: Evaluate iron intake adequacy
• Test for Helicobacter pylori: This infection impairs iron absorption 3
• Screen for celiac disease: If suspected, as it causes malabsorption 3

Step 2: Iron Replacement Therapy

Initiate oral iron supplementation as first-line therapy 3:

• Ferrous salts (ferrous sulfate, ferrous fumarate, or ferrous gluconate) are reasonable first choices due to cost-effectiveness 3
• Dosing: Take on an empty stomach for optimal absorption; if not tolerated, take with meals 3
• Enhance absorption: Co-administer with 500 mg vitamin C or take with meat protein 3
• Alternative formulations: Consider ferrous bisglycinate if standard ferrous salts are poorly tolerated 3

Consider intravenous iron if 3:

• Severe iron deficiency at presentation
• Oral iron intolerance (nausea, abdominal pain, constipation)
• Conditions causing malabsorption (celiac disease, inflammatory bowel disease)
• Failure to improve iron stores with oral supplementation

Step 3: Monitor Platelet Response

The thrombocytosis will resolve with iron replacement—no specific antiplatelet therapy is needed 1:

• 50% of patients: Platelet count normalizes within 2 weeks of iron supplementation 1
• 100% of patients: Thrombocytosis resolves within 6 weeks of treatment 1
• Follow-up frequency: Recheck CBC at 2-week intervals initially to monitor both hemoglobin and platelet response 1

Step 4: Thrombosis Risk Assessment

Low-dose aspirin is NOT routinely indicated for reactive thrombocytosis unless there are additional cardiovascular risk factors. The thrombocytosis in this case (443 × 10⁹/L) is mild and will resolve with iron treatment.

However, be vigilant for thrombotic complications in severe cases (platelets >1000 × 10⁹/L), which can rarely cause cerebral venous thrombosis or other thrombotic events 6, 7. This patient's platelet count does not reach this threshold.

Critical Pitfalls to Avoid

1. Do not assume normal ferritin excludes iron deficiency: In inflammatory states, ferritin can be falsely elevated. Use the 45 μg/L threshold and consider transferrin saturation or soluble transferrin receptor if uncertainty exists 3, 2.

2. Do not treat thrombocytosis with cytoreductive therapy: This is reactive, not primary thrombocytosis. Hydroxyurea or other myelosuppressive agents are contraindicated 8, 9.

3. Do not delay investigation of the iron loss source: Simply replacing iron without identifying the cause (especially GI malignancy in older adults) can lead to missed diagnoses 2.

4. Do not overlook persistent thrombocytosis after 6 weeks of adequate iron replacement: If platelets remain elevated despite corrected iron stores, consider a concomitant myeloproliferative neoplasm and test for JAK2, CALR, and MPL mutations 1, 9.

Expected Outcomes

With appropriate iron replacement:

• Reticulocyte count: Will initially rise further (peak at 7-10 days), then normalize
• Hemoglobin: Should increase by 1-2 g/dL every 2-3 weeks
• Platelet count: Normalizes within 2-6 weeks 1
• MCV and MCH: Gradually normalize over 2-3 months

Continue iron supplementation for 3-6 months after hemoglobin normalization to replenish iron stores 3.